B
Biofourmis
Biotechnology company that augments personalized care and therapies using digital therapeutics
At a glance
- Founded
- 2015
- Headquarters
- Boston, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Research & analysis
Latest news
Press, funding announcements and product moves mentioning Biofourmis.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- EIEden Strategy Institute
- SPSpesNet Pte.
Series A2 investors entered at this stage
- OVOpenspace Ventures
- AVAviva Ventures
Series B and later10 investors entered at this stage
Sequoia- CHCVS Health
- JCJinke Entertainment Culture
General Atlantic
SoftBank Vision Fund- MVMassMutual Ventures
- EDEDBI
Intel Capital
SoftBank- SGSGInnovate
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Investments and acquisitions
Disclosed deals where Biofourmis was the backer or acquirer, 2019–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Biofourmis's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Biofourmis's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biofourmis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biofourmis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.